
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9949246/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
2	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. Clinical Cancer Research, 2016, 22, 5223-5228.	3.2	112
3	Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia, 2019, 33, 1035-1038.	3.3	48
4	Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. Oncotarget, 2017, 8, 72182-72196.	0.8	43
5	câ€Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/Tâ€cell lymphoma. Journal of Cellular Biochemistry, 2019, 120, 12628-12637.	1.2	36
6	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. Cancer Biology and Therapy, 2019, 20, 31-41.	1.5	32
7	Lymphoma associated hemophagocytic syndrome: A single‑center retrospective study. Oncology Letters, 2018, 16, 1275-1284.	0.8	28
8	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Investigational New Drugs, 2020, 38, 1847-1853.	1.2	28
9	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus <scp>CHOP</scp> in patients with newly diagnosed peripheral Tâ€cell lymphoma with analysis of biomarkers. British Journal of Haematology, 2017, 178, 772-780.	1.2	25
10	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. Nature Communications, 2019, 10, 4209.	5.8	25
11	Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. Scientific Reports, 2017, 7, 41057.	1.6	23
12	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitisâ€like Tâ€cell lymphoma. British Journal of Haematology, 2018, 181, 406-410.	1.2	22
13	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. Journal of Neuro-Oncology, 2018, 140, 427-434.	1.4	22
14	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. Oncotarget, 2016, 7, 53808-53819.	0.8	21
15	Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. JAMA Oncology, 2022, 8, 1035.	3.4	21
16	Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma. Journal of Magnetic Resonance Imaging, 2016, 44, 1522-1529.	1.9	19
17	TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway. Journal of Translational Medicine, 2018, 16, 7.	1.8	19
18	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDCP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. Oncotarget, 2016, 7, 55721-55731.	0.8	19

#	Article	IF	CITATIONS
19	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. Leukemia Research, 2015, 39, 1448-1454.	0.4	18
20	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. Molecular Medicine, 2018, 24, 35.	1.9	18
21	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. Experimental Cell Research, 2018, 364, 125-132.	1.2	14
22	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. Oncology Letters, 2016, 11, 693-698.	0.8	13
23	B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. Scientific Reports, 2018, 8, 12907.	1.6	13
24	<p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p> . OncoTargets and Therapy, 2020, Volume 13, 7189-7197.	1.0	13
25	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma Journal of Clinical Oncology, 2020, 38, 3026-3026.	0.8	13
26	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. Blood, 2021, 138, 3829-3829.	0.6	13
27	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2613-2618.	0.6	12
28	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. Oncology Letters, 2016, 12, 4173-4180.	0.8	12
29	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Annals of Hematology, 2021, 100, 1509-1516.	0.8	11
30	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen. Blood, 2019, 134, 463-463.	0.6	11
31	Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival. Biochemical and Biophysical Research Communications, 2018, 504, 525-531.	1.0	10
32	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/Tâ€cell lymphoma: A randomized, controlled, openâ€label, multicenter study. International Journal of Cancer, 2021, 148, 1470-1477.	2.3	10
33	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. Oncotarget, 2018, 9, 16213-16219.	0.8	10
34	<p>Clinical features and prognostic factors of primary bone marrow lymphoma</p> . Cancer Management and Research, 2019, Volume 11, 2553-2563.	0.9	9
35	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. European Journal of Radiology, 2020, 133, 109301.	1.2	9
36	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) <i>versus</i> CHOP in newly diagnosed peripheral T-cell lymphoma patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092382.	1.4	9

#	Article	IF	CITATIONS
37	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. Frontiers in Oncology, 2021, 11, 687374.	1.3	9
38	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. Cancer Research and Treatment, 2021, 53, 837-846.	1.3	9
39	Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. Oncology Letters, 2015, 10, 3261-3265.	0.8	8
40	MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. Anti-Cancer Drugs, 2018, 29, 861-870.	0.7	8
41	Analyses and treatment of simultaneous bi‑lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. Oncology Letters, 2018, 16, 6624-6632.	0.8	8
42	<p>Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study</p> . Cancer Management and Research, 2019, Volume 11, 1363-1372.	0.9	8
43	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/Tâ€cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. Clinical and Translational Science, 2021, 14, 405-411.	1.5	8
44	Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes. Medicine (United States), 2017, 96, e7111.	0.4	7
45	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. Haematologica, 2020, 105, e107-e110.	1.7	7
46	<prognostic analysis="" and<br="" b-cell="" cd5="" diffuse="" double-hit="" expression="" in="" large="" lymphoma="" of="">effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. Blood and Lymphatic Cancer: Targets and Therapy, 2019, Volume 9, 33-43.</prognostic>	1.2	6
47	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. Drug Design, Development and Therapy, 2020, Volume 14, 275-284.	2.0	6
48	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. Aging, 2019, 11, 3939-3957.	1.4	6
49	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. Oncology Letters, 2014, 8, 886-890.	0.8	4
50	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. Cancer Cell International, 2018, 18, 150.	1.8	3
51	Clinical analysis of patients with primary and secondary extranodal natural killer/Tâ€cell lymphoma of central nervous system. Hematological Oncology, 2023, 41, 267-274.	0.8	3
52	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. Frontiers in Cellular and Infection Microbiology, 2021, 11, 686595.	1.8	3
53	ORP8 induces apoptosis by releasing cytochrome�c from mitochondria in non‑small cell lung cancer. Oncology Reports, 2020, 43, 1516-1524.	1.2	3
54	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. Blood, 2021, 138, 3830-3830.	0.6	3

#	Article	IF	CITATIONS
55	CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes. Leukemia Research, 2022, 117, 106840.	0.4	3
56	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. Oncology Letters, 2018, 15, 8034-8038.	0.8	2
57	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 42-50.	0.3	2
58	Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. Cancer Biology and Medicine, 2021, 19, 1089-1099.	1.4	1
59	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial. Blood, 2021. 138. 1368-1368.	0.6	1
60	GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). Blood, 2016, 128, 2989-2989.	0.6	0
61	Primary Testicular Lymphoma:a Single Center Experience and Literature Review. Blood, 2016, 128, 5415-5415.	0.6	0
62	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. Blood, 2019, 134, 2873-2873.	0.6	0
63	Outcomes of GDPT (gemcitabine, cisplatin, prednisone,thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients Journal of Clinical Oncology, 2020, 38, 8018-8018.	0.8	0
64	Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway. Blood, 2020, 136, 46-47.	0.6	0
65	Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial. Blood, 2020, 136, 5-5.	0.6	0
66	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation. Leukemia and Lymphoma, 2022, , 1-6.	0.6	0